Northern Trust’s Tourmaline Bio TRML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-162,540
| Closed | -$7.77M | – | 4547 |
|
|
2025
Q3 | $7.77M | Sell |
162,540
-10,736
| -6% | -$298K | ﹤0.01% | 2254 |
|
|
2025
Q2 | $2.77M | Sell |
173,276
-29,306
| -14% | -$475K | ﹤0.01% | 2804 |
|
|
2025
Q1 | $3.08M | Sell |
202,582
-2,204
| -1% | -$35.3K | ﹤0.01% | 2683 |
|
|
2024
Q4 | $4.15M | Buy |
204,786
+13,603
| +7% | +$343K | ﹤0.01% | 2615 |
|
|
2024
Q3 | $4.92M | Buy |
191,183
+143,769
| +303% | +$2.4M | ﹤0.01% | 2486 |
|
|
2024
Q2 | $610K | Buy |
47,414
+11,312
| +31% | +$182K | ﹤0.01% | 3435 |
|
|
2024
Q1 | $827K | Buy |
36,102
+13,729
| +61% | +$484K | ﹤0.01% | 3393 |
|
|
2023
Q4 | $586K | Buy |
22,373
+19,327
| +635% | +$387K | ﹤0.01% | 3494 |
|
|
2023
Q3 | $85.6K | Buy |
3,046
+545
| +22% | +$16K | ﹤0.01% | 4049 |
|
|
2023
Q2 | $76K | Sell |
2,501
-13,835
| -85% | -$353K | ﹤0.01% | 4109 |
|
|
2023
Q1 | $307K | Sell |
16,336
-331
| -2% | -$5.46K | ﹤0.01% | 3661 |
|
|
2022
Q4 | $170K | Sell |
16,667
-707
| -4% | -$11.4K | ﹤0.01% | 3935 |
|
|
2022
Q3 | $457K | Buy |
17,374
+1,106
| +7% | +$40.3K | ﹤0.01% | 3546 |
|
|
2022
Q2 | $734K | Sell |
16,268
-166
| -1% | -$13.1K | ﹤0.01% | 3420 |
|
|
2022
Q1 | $1.62M | Sell |
16,434
-371
| -2% | -$34.7K | ﹤0.01% | 3196 |
|
|
2021
Q4 | $2.57M | Buy |
16,805
+8,506
| +102% | +$1.26M | ﹤0.01% | 3102 |
|
|
2021
Q3 | $1.13M | Sell |
8,299
-979
| -11% | -$134K | ﹤0.01% | 3514 |
|
|
2021
Q2 | $1.36M | Buy |
+9,278
| New | +$1.42M | ﹤0.01% | 3458 |
|
Northern Trust's TRML Position: Q4 2025 in Review
Northern Trust sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 162,540 shares — an estimated $7.77M sold.
Northern Trust first reported a position in TRML in Q2 2021 and held it in 18 quarters. The position peaked at $7.77M in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.
- Northern Trust reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
- Northern Trust sold 162,540 Tourmaline Bio shares in Q4 2025, an estimated $7.77M.
- Northern Trust first reported a position in Tourmaline Bio in Q2 2021 and held it in 18 quarters.
- Northern Trust's Tourmaline Bio position peaked at $7.77M in Q3 2025.
- 0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.
Based on Northern Trust's 13F filing for Q4 2025, filed 17 Feb 2026.